The U.S. Supreme Court decided today to consider the patent-eligibility of isolated DNA sequences by reviewing the Federal Circuit’s decision – Ass’n for Molecular Pathology v. Myriad Genetics, Inc., No. 2010-1406 (Fed. Cir. 2012).
Related Insights
October 8, 2025
Personalized Medicine Bulletin
From Abstract to Applied: How Desjardins Can Reframe Patent Protection for AI in Health Care
For a decade, innovators at the intersection of artificial intelligence (AI) and precision medicine have faced a stubborn paradox: the…
May 28, 2025
Personalized Medicine Bulletin
Rethinking University Research: Innovating the Innovation Ecosystem to Support Life Sciences and Personalized Medicine
Personalized medicine—tailoring treatments to individual patients based on their genetic makeup, lifestyle, and environment—is…
August 29, 2023
Personalized Medicine Bulletin
NIH Funded Research Centers Support Precision Medicine Research
Somatic mosaicisms are post-conception changes to cellular DNA that lead to genetic variation among cells in an organism.